(NP -LCB-/-LRB- (NP Regulatory/JJ effect/NN) (PP of/IN (NP insulin/NN)) (PP on/IN (NP (NP glucocorticoid/NN receptor/NN) (PP in/IN (NP human/JJ peripheral/JJ leukocytes/NNS)))) -RCB-/-RRB-)
(S (NP-SBJ-8 (NP The/DT regulatory/JJ effect/NN) (PP of/IN (NP insulin/NN)) (PP on/IN (NP (NP the/DT specific/JJ binding/VBG power/NN) (PP of/IN (NP (NP (NP glucocorticoid/NN receptor/NN) (PRN -LRB-/-LRB- (NP GR/NN) -RRB-/-RRB-)) (PP of/IN (NP human/JJ leukocytes/NNS))))))) (VP was/VBD (VP assessed/VBN (NP *-8/-NONE-) (PP by/IN (NP (NP the/DT unoccupied/JJ receptor/NN sites/NNS) (ADJP capable/JJ (PP of/IN (S (NP-SBJ */-NONE-) (VP combining/VBG (PP with/IN (NP (NP -LCB-3H-RCB-/NN labelled/JJ dexamethasone/NN) (VP measured/VBN (NP */-NONE-) (PP-TMP at/IN (NP (NP (QP 3/CD and/CC 24/CD) h/NN) (PP-TMP after/IN (NP incubation/NN (PP with/IN (NP (NP various/JJ concentrations/NNS) (PP of/IN (NP insulin/NN)) (VP added/VBN (NP */-NONE-) (PP to/TO (NP the/DT medium/NN)))))))))))))))))))) ./.)
(S (PP-TMP After/IN (NP (ADJP 3/CD h/NN) incubation/NN)) (NP-SBJ-10 (NP the/DT specific/JJ binding/VBG power/NN) (PP with/IN (NP -LCB-3H-RCB-/NN Dex/NN))) (VP was/VBD (VP decreased/VBN (NP *-10/-NONE-) (PP by/IN (NP (NP (NP-COOD (NP (QP 23.3/CD +\/-/CC 10.0/CD) (NP *RNR*-90/-NONE-)) ,/, (NP (QP 32.2/CD +\/-/CC 13.2/CD) (NP *RNR*-90/-NONE-)) and/CC (NP (QP 54.3/CD +\/-/CC 9.2/CD) (NP *RNR*-90/-NONE-))) (NP-90 %/NN)) (PRN -LRB-/-LRB- (NP (NP-COOD (NP (NP P/NN) (ADJP (ADJP greater/JJR) (PP than/IN (NP 0.05/CD)))) ,/, (NP (NP P/NN) (ADJP (ADJP greater/JJR) (PP than/IN (NP 0.05/CD)))) and/CC (NP (NP P/NN) (ADJP (ADJP less/JJR) (PP than/IN (NP 0.01/CD))))) (SBAR as/IN (S (NP-SBJ-11 */-NONE-) (VP compared/VBN (NP *-11/-NONE-) (PP with/IN (NP (NP (NP the/DT control/NN value/NN) (PP of/IN (NP 100/CD))) (PP in/IN the/DT absence/NN of/IN (NP insulin/NN)))))))) -RRB-/-RRB-))) (ADVP respectively/RB) (PP in/IN the/DT presence/NN of/IN (NP (NP (NP-COOD (NP (NP 20/CD mU\/L/NN) (PRN -LRB-/-LRB- (NP physiological/JJ testing/NN concentration/NN) -RRB-/-RRB-)) ,/, (NP (NP 200/CD mU\/L/NN) (PRN -LRB-/-LRB- (NP physiological/JJ upper/JJ limit/NN) -RRB-/-RRB-)) and/CC (NP (NP 2,000/CD mU\/L/NN) (PRN -LRB-/-LRB- (NP pharmacological/JJ concentration/NN) -RRB-/-RRB-))) insulin/NN) (PP in/IN (NP the/DT incubation/NN medium/NN)))))) ./.)
(S (PP-TMP After/IN (NP (ADJP 24/CD h/NN) incubation/NN)) (NP-SBJ (NP the/DT decrease/NN) (PP of/IN (NP these/DT values/NNS))) (VP increased/VBD (ADVP respectively/RB) (PP to/TO (NP (NP-COOD (NP (QP 43.5/CD +\/-/CC 19.0/CD)) ,/, (NP (QP 56.1/CD +\/-/CC 20.7/CD)) and/CC (NP (QP 80.2/CD +\/-/CC 15.5/CD))) (PRN -LRB-/-LRB- (NP (NP-COOD (NP (NP P/NN) (ADJP (ADJP less/JJR) (PP than/IN (NP 0.05/CD)))) ,/, (NP (NP P/NN) (ADJP (ADJP less/JJR) (PP than/IN (NP 0.01/CD)))) and/CC (NP (NP P/NN) (ADJP (ADJP less/JJR) (PP than/IN (NP 0.01/CD))))) (S (NP-SBJ-92 */-NONE-) (VP compared/VBN (NP *-92/-NONE-) (PP with/IN (NP control/NN))))) -RRB-/-RRB-)))) ./.)
(S (ADVP Thus/RB) (NP-SBJ (NP the/DT inhibitory/JJ effect/NN) (PP of/IN (NP insulin/NN)) (PP on/IN (NP the/DT GR/NN binding/NN power/NN))) (VP (VP is/VBZ (ADJP-PRD both/CC (ADJP-COOD (ADJP (NP dose-/NN) (ADJP *?*/-NONE-)) and/CC (ADJP time-dependent/JJ)))) ,/, (SBAR (WHNP-12 which/WDT) (S (NP-SBJ *T*-12/-NONE-) (ADVP strongly/RB) (VP suggests/VBZ (SBAR that/IN (S (NP-SBJ-13 GR/NN) (VP is/VBZ (ADVP tonically/RB) (VP controlled/VBN (NP *-13/-NONE-) (PP by/IN (NP-LGS (NP insulin/NN concentration/NN change/NN) (PP under/IN (NP physiological/JJ conditions/NNS)))))))))))) ./.)
